Home / Health / GSK Bets $110M on Novel Cancer Drug
GSK Bets $110M on Novel Cancer Drug
3 Sep
Summary
- GSK secures global rights to HMPL-A830, a novel solid tumor drug.
- The deal with HUTCHMED could reach a total value of $1.295 billion.
- HMPL-A830 targets KRAS mutations, prevalent in many cancers.
GSK has entered into a significant licensing agreement with HUTCHMED, securing global rights to the novel cancer candidate HMPL-A830. The upfront payment for this deal is $110 million, with potential milestone payments reaching $1.185 billion, bringing the total deal value to $1.295 billion. HUTCHMED will continue to lead development and commercialization activities within Mainland China, Hong Kong, Macau, and Taiwan.
HMPL-A830 represents a new class of therapy known as an antibody-targeted therapy conjugate (ATTC). Unlike traditional antibody-drug conjugates, ATTCs utilize a KRAS small molecule inhibitor payload attached to an anti-EGFR antibody. This design allows for potent anti-tumor activity and greater durability by delivering the inhibitor directly to EGFR-expressing tumors and simultaneously blocking KRAS and EGFR signaling pathways.
KRAS mutations are a key driver in a significant portion of human cancers, affecting roughly 15% to 20% of all cases. This includes high prevalence in colorectal, lung adenocarcinoma, and pancreatic ductal adenocarcinoma. The development of HMPL-A830 will initially focus on these three indications. HUTCHMED plans to initiate a global Phase I development program in the second half of 2026, which will assess the drug's safety and efficacy in patients with advanced or metastatic solid tumors refractory to standard treatments.
